Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.63 |
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368753 | 1.00 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL18262439 | 0.89 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL18262437 | 0.89 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL16448191 | 0.89 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL231980 | 0.89 | CTSS (0.71) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL25284980 | 0.89 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1310547 | 0.89 | CTSS (0.71) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL9502547 | 0.89 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1458942 | 0.89 | PPARA (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL25672 | 0.89 | PPARA (0.65) | ACEITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658866-A | Synthesis method of azido amino acid derivative | 苏州爱玛特生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4097092-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Protego Biopharma, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-108047086-A | Composition containing alpha-non-natural amino acid and polypeptide, be related to the method for alpha-non-natural amino acid and polypeptide with and application thereof | AMBRX公司 | 2018-05-18 | — | — | CN | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-1828224-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-1828224-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1828224-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | Ambrx, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060217289-A1 | Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| WO-2006069246-A9 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006069246-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | ACE 87/4885ITGB3 4718/4885ITGA2B 4784/4885 |
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | ACE 1595/4885ITGB3 1236/4885ITGA2B 1192/4885 |
| US-20060217289-A1 | Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid | DAO, OSGEP, OTC | ACE 2741/4885ITGB3 1861/4885ITGA2B 1954/4885 |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | DAO, DNPEP, PTMS | ACE 2266/4885ITGB3 1173/4885ITGA2B 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.